IAM
NRIX icon

Innovis Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Innovis Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,648
Closed -$156K – 168
2023
Q2 		$156K Sell
15,648
-14,397
-48% -$147K 0.06% 154
2023
Q1 		$267K Buy
+30,045
New +$313K 0.11% 123

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Innovis Asset Management's NRIX Position: Q3 2023 in Review

Innovis Asset Management sold out of Nurix Therapeutics (NRIX) in Q3 2023, closing a stake of 15,648 shares — an estimated $156K sold.

Innovis Asset Management first reported a position in NRIX in Q1 2023 and held it in 2 quarters. The position peaked at $267K in Q1 2023. 128 funds tracked by Wall St. Rank hold NRIX as of Q3 2023.

  • Innovis Asset Management reported no remaining Nurix Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Innovis Asset Management sold 15,648 Nurix Therapeutics shares in Q3 2023, an estimated $156K.
  • Innovis Asset Management first reported a position in Nurix Therapeutics in Q1 2023 and held it in 2 quarters.
  • Innovis Asset Management's Nurix Therapeutics position peaked at $267K in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.